Biography for Mark Hollmer
Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.
Articles by Mark Hollmer
AngioDynamics said it won expanded FDA clearance for one of its key vascular access devices, a development that could help it boost the market reach for a product it bills as a healthcare cost-cutter.
Roche's Ventana Medical Systems and Bayer Pharma have decided to extend and expand a companion diagnostic collaboration first launched in 2012, another steady advance in personalized medicine.
California's TriVascular Technologies is betting it can broaden the reach of its FDA-approved stent grafts to treat abdominal aortic aneurysms and has filed plans to raise up to $100 million in an IPO to help accomplish its goal.
Lombard Medical is disclosing IPO details following its initial announcement in January. The U.K. maker of an aortic repair device said it plans to raise up to $80 million, and will trade on the Nasdaq under the symbol "EVAR," according to a regulatory filing.
German medical device manufacturer Gerresheimer AG is expanding its presence in Georgia to take advantage of a boom in inhaler and insulin-pen demand. The investment is in the millions of dollars and will create additional 120 jobs in the process.
Smith & Nephew has inked a co-marketing deal with OrthoSensor involving one of the company's orthopedic surgical tools. Neither side is discussing financial details.
For the first time, a blood test appears to predict with an impressive level of certainty whether patients will develop Alzheimer's disease within three years.
Invuity's $36 million Series E debt and equity round announced last week will back a beefed up sales force, plus an expanded headquarters and manufacturing operation for its illumination technology and surgical tools. But is an IPO next? CEO Phil Sawyer isn't saying either way, choosing to remain mum about the San Francisco-based company's future financing plans.
Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
AngioDynamics is gearing up for commercialization in the coming year for its latest chronic dialysis cathether, a product that will help protect and grow an already impressive U.S. market presence.